Operating Lease, Right-of-Use Asset of TScan Therapeutics, Inc. from 31 Dec 2020 to 31 Dec 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of lessee's right to use underlying asset under operating lease.
Summary
TScan Therapeutics, Inc. quarterly Operating Lease, Right-of-Use Asset in USD history and change rate from 31 Dec 2020 to 31 Dec 2025.
  • TScan Therapeutics, Inc. Operating Lease, Right-of-Use Asset for the quarter ending 31 Dec 2025 was $57,743,000, a 10% decline year-over-year.
Source SEC data
View on sec.gov
Operating Lease, Right-of-Use Asset, Quarterly (USD)
Operating Lease, Right-of-Use Asset, YoY Quarterly Change (%)

TScan Therapeutics, Inc. Quarterly Operating Lease, Right-of-Use Asset (USD)

Period Value YoY Chg Change % Date Report Filed Fiscal Year Fiscal Period
Q4 2025 $57,743,000 -$6,614,000 -10% 31 Dec 2025 10-K 04 Mar 2026 2025 FY
Q3 2025 $59,438,000 -$205,000 -0.34% 30 Sep 2025 10-Q 12 Nov 2025 2025 Q3
Q2 2025 $61,097,000 +$148,000 +0.24% 30 Jun 2025 10-Q 12 Aug 2025 2025 Q2
Q1 2025 $62,736,000 +$504,000 +0.81% 31 Mar 2025 10-Q 06 May 2025 2025 Q1
Q4 2024 $64,357,000 +$865,000 +1.4% 31 Dec 2024 10-K 04 Mar 2026 2025 FY
Q3 2024 $59,643,000 +$1,104,000 +1.9% 30 Sep 2024 10-Q 12 Nov 2024 2024 Q3
Q2 2024 $60,949,000 +$1,128,000 +1.9% 30 Jun 2024 10-Q 12 Aug 2024 2024 Q2
Q1 2024 $62,232,000 +$4,318,000 +7.5% 31 Mar 2024 10-Q 13 May 2024 2024 Q1
Q4 2023 $63,492,000 +$4,390,000 +7.4% 31 Dec 2023 10-K 05 Mar 2025 2024 FY
Q3 2023 $58,539,000 +$54,171,000 +1240% 30 Sep 2023 10-Q 09 Nov 2023 2023 Q3
Q2 2023 $59,821,000 +$55,071,000 +1159% 30 Jun 2023 10-Q 10 Aug 2023 2023 Q2
Q1 2023 $57,914,000 +$52,789,000 +1030% 31 Mar 2023 10-Q 10 May 2023 2023 Q1
Q4 2022 $59,102,000 +$53,611,000 +976% 31 Dec 2022 10-K 06 Mar 2024 2023 FY
Q3 2022 $4,368,000 -$1,462,000 -25% 30 Sep 2022 10-Q 09 Nov 2022 2022 Q3
Q2 2022 $4,750,000 -$1,435,000 -23% 30 Jun 2022 10-Q 10 Aug 2022 2022 Q2
Q1 2022 $5,125,000 31 Mar 2022 10-Q 12 May 2022 2022 Q1
Q4 2021 $5,491,000 -$1,382,000 -20% 31 Dec 2021 10-K 08 Mar 2023 2022 FY
Q3 2021 $5,830,000 30 Sep 2021 10-Q 10 Nov 2021 2021 Q3
Q2 2021 $6,185,000 30 Jun 2021 10-Q 19 Aug 2021 2021 Q2
Q4 2020 $6,873,000 31 Dec 2020 10-K 09 Mar 2022 2021 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.